DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) was upgraded by equities research analysts at BMO Capital Markets to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.
Several other equities analysts have also recently weighed in on XRAY. UBS Group dropped their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Citigroup assumed coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective for the company. Mizuho lowered their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Barclays dropped their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. Finally, Weiss Ratings downgraded DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $13.42.
Check Out Our Latest Stock Report on DENTSPLY SIRONA
DENTSPLY SIRONA Stock Performance
DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same period last year, the business posted $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts forecast that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Brian T. Gladden acquired 9,985 shares of the stock in a transaction on Monday, June 15th. The shares were acquired at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the transaction, the director owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael J. Barber bought 15,175 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the purchase, the director owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. The trade was a 37.22% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 35,160 shares of company stock worth $351,179. Insiders own 0.46% of the company’s stock.
Hedge Funds Weigh In On DENTSPLY SIRONA
Several institutional investors have recently bought and sold shares of the company. Southpoint Capital Advisors LP bought a new position in DENTSPLY SIRONA during the first quarter valued at $116,000,000. AQR Capital Management LLC raised its stake in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after buying an additional 6,970,086 shares during the period. Armistice Capital LLC lifted its position in shares of DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after buying an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of DENTSPLY SIRONA by 662.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after buying an additional 4,003,606 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.
About DENTSPLY SIRONA
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Read More
- Five stocks we like better than DENTSPLY SIRONA
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
